Sensorion announces that the primary endpoint of the Phase 2a clinical study of SENS-401 in the preservation of residual hearing has been achieved
•
The presence of SENS-401 is confirmed in the perilymph in 100% of patients sampled after cochlear implantation, at a level compatible with potential therapeutic efficacy.
Montpellier, March 11, 2024, at 7:30 a.m. – Sensorion (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company specializing in the development of new therapies to restore, treat and prevent hearing loss disorders, today announces that it has achieved the primary endpoint of its Phase 2a proof-of-concept (POC) clinical trial of SENS-401 for the preservation of residual hearing after cochlear implantation.